"L'IUCT Oncopole est composé de l'Institut Claudius Regaud, centre de lutte contre le cancer et de plusieurs équipes du CHU de Toulouse. Sur un même site, les deux établissements réunissent l'expertise de 1500 professionnels spécialisés en cancérologie. L'Institut est situé au cœur d'un campus regroupant des acteurs privés et publics investis dans la lutte contre le cancer. Trois missions lui sont confiées : le soin, la recherche et l'enseignement."

During the past decade, Hopital Purpan Service d'Hématologie Clinique conducted 1 clinical trials. In the 10-year time frame, 1 clinical trials started and 2 clinical trials were completed, i.e. on average, 200% percent of trials that started reached the finish line to date. In the past 5 years, 0 clinical trials started and 1 clinical trials were completed. i.e. 0% of trials that started reached the finish line.

In terms of collaborators to trials, out of the total clinical trials conducted in "Hopital Purpan Service d'Hématologie Clinique" #1 collaborator was "Merck Sharp & Dohme LLC" with 2 trials as a collaborator, "Astex Pharmaceuticals, Inc." with 1 trials as a collaborator, "Celgene" with 1 trials as a collaborator, "Celgene Corporation" with 1 trials as a collaborator and "EpiCept Corporation" with 1 trials as a collaborator. Other collaborators include -2 different institutions and companies that were collaborators in the rest 8 trials.

According to Clinical.Site data, the most researched conditions in "Hopital Purpan Service d'Hématologie Clinique" are "Myelodysplastic Syndrome" (3 trials), "Myelodysplastic Syndromes" (3 trials), "Acute Myeloid Leukemia" (2 trials), "Chronic Myelomonocytic Leukemia" (2 trials) and "B-cell Lymphoma" (1 trials). Many other conditions were trialed in "Hopital Purpan Service d'Hématologie Clinique" in a lesser frequency.

Most popular intervention types in "Hopital Purpan Service d'Hématologie Clinique" are "Drug" (13 trials). Other intervention types were less common.

The name of intervention was led by "Azacitidine" (2 trials), "Rituximab" (2 trials), "Azacitidine and oral vorinostat" (1 trials), "Azacitidine combined to Lenalidomide" (1 trials) and "Bevacizumab" (1 trials). Other intervention names were less common.

The vast majority of trials in "Hopital Purpan Service d'Hématologie Clinique" are 13 trials for "All" genders.

Currently, there are NaN active trials in "Hopital Purpan Service d'Hématologie Clinique". undefined are not yet recruiting, undefined are recruiting, undefined are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 9 completed trials in Hopital Purpan Service d'Hématologie Clinique, undefined suspended trials, and 2 terminated clinical trials to date.

Out of the total trials that were conducted in Hopital Purpan Service d'Hématologie Clinique, 4 "Phase 1" clinical trials were conducted, 10 "Phase 2" clinical trials and 3 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 0 trials that are defined as “Not Applicable".